Abstract
Recent publications suggest that tyrosinase mRNA in blood as well as in bone marrow is detectable only in a subgroup of patients with metastatic melanoma. This would imply that tyrosinase mRNA is of limited value as a tumor marker. We addressed the question of whether patients with metastatic melanoma and RT-PCR-detectable tyrosinase mRNA in blood or bone marrow have a different prognosis than tyrosinase mRNA-negative patients. Twenty melanoma patients with widespread clinical metastases were enrolled; the survival time after first diagnosis of visceral metastases was correlated to tyrosinase mRNA presence in blood and bone marrow samples. The time of survival of eight patients with metastatic melanoma and detectable tyrosinase mRNA in either blood or bone marrow was not different from the prognosis of 12 patients without detectable tyrosinase mRNA in either blood or bone marrow. Detection of tyrosinase mRNA in blood or bone marrow samples of melanoma patients with advanced disease seems to have no substantial relevance for survival time and outcome of disease. In this constellation, detection of tyrosinase mRNA by RT-PCR is not a valid tumor marker. Nevertheless, tyrosinase positivity in bone marrow in earlier tumor stages might indicate increased risk for the development of distant metastases. This should be addressed in further studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bennet DJ. Colour genes, oncogenes and melanocytes differentiation (1991) J Cell Sci 98: 135–139
Boyum A (1968) Separation of leukocytes from blood and bone marrow. Scand J Clin Invest 21: 51–55
Burchill S, Bradbury M, Pittman K, Southgate J, Smith B, Selby P (1995) Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. Br J Cancer 71: 278–281
Curry B, Smith M, Hersey P (1996) Detection and quantitation of melanoma cells in the circulation of patients. Melanoma Res 6: 45–54
Farthmann B, Eberle J, Krasagakis K, Gstöttner M, Wang N, Bisson S, Orfanos C (1998) RTPCR for tyrosinase-mRNA-positive cells in peripheral blood: Evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol 110: 263–267
Ghossein R, Coit D, Brennan M, Zhang Z, Wang Y, Bhattacharya S, Houghton A, Rosai J (1998) Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 4: 419–428
Hoon DS, Wang Y, Dale PS et al. (1995) Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13: 2109–2116
Lindemann F, Schlimok G, Dirschedl P et al. (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340: 685–689
Rankin E (1996) Detection of early micrometastases in malignant melanoma. Europ J Cancer 32 A: 1627–1629
Sarantou T, Chi DD, Garrison DA et al. (1997) Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57: 1371–1376
Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair G (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338: 1227–1229
de Vries TJ, Fourkour A, Wobbes T et al. (1997) Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1 and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 57: 3223–3229
Waldmann V, Deichmann M, Jäckel A (2000) Minimal residual disease in metastatic melanoma and its detection by tumor marker candidates. Hautarzt (in press)
Waldmann V, Deichmann M, Bock M, Jäckel A, Näher H (1999) Tyrosinase-specific mRNA in bone marrow is not more sensitive than blood for the demonstration of micrometastatic melanoma. Br J Dermatol 140: 1060–1064
Waldmann V, Deichmann M, Bock M, Jäckel A, Näher H (1999) Tyrosinase-specific mRNA in bone marrow is not more sensitive than blood for the demonstration of micrometastatic melanoma. Br J Dermatol 140: 1060–1064
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Waldmann, V., Wacker, J., Deichmann, M., Jäckel, A., Bock, M., Näher, H. (2001). Prognosis of Metastatic Melanoma: No Correlation of Tyrosinase mRNA in Bone Marrow and Survival Time. In: Reinhold, U., Tilgen, W. (eds) Minimal Residual Disease in Melanoma. Recent Results in Cancer Research, vol 158. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59537-0_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-59537-0_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64015-5
Online ISBN: 978-3-642-59537-0
eBook Packages: Springer Book Archive